BIGBEAR
PHARMACEUTICAL
Binimetinib is a targeted anti-cancer drug that works by blocking the MEK protein (a key protein that stimulates cancer cell growth) within cancer cells, thereby inhibiting tumor growth.
AuthenticGuaranteeFast DeliveryPrivacy On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination regimen of Binimetinib and Encorafenib for the treatment of pat···【More】
Update: 12 May,2026Source: BigbearViews: 110
October 12, 2023 – New York – (Business Wire)Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi®···【More】
Update: 12 May,2026Source: BigbearViews: 115
Binimetinib is indicated for use in combination with encorafenib for the treatment of advanced melanoma and non-small cell lung cancer (NSCLC) harbori···【More】
Update: 12 May,2026Source: BigbearViews: 110
In June 2018, the U.S. Food and Drug Administration (FDA) approved binimetinib for marketing as a treatment for unresectable metastatic melanoma or me···【More】
Update: 05 Mar,2026Source: BigbearViews: 118
Binimetinib, developed by Pierre Fabre in France, was approved by the U.S. Food and Drug Administration (FDA) in 2018, providing a new treatment optio···【More】
Update: 04 Mar,2026Source: BigbearViews: 112
Binimetinib is often used in combination with encorafenib. These two drugs target the same signaling pathway at different points and can synergistical···【More】
Update: 04 Mar,2026Source: BigbearViews: 103
While binimetinib offers a new treatment option for melanoma patients, its potential adverse reactions still require careful monitoring during use.Sid···【More】
Update: 04 Mar,2026Source: BigbearViews: 104
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
